Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs (STTK) plans to start a Phase 2 trial in 2026 for SL-325 in hidradenitis suppurativa, with data expected in 2028. The company also appointed Shoba Ravichandran as Senior Vice President, Clinical Development. Cash runway is expected to last until 2029.
How this was made
The 30-second read
Why it matters
The new Phase 2 trial expands SL-325 into hidradenitis suppurativa, a disease with unmet need, potentially broadening the drug's market.
Market read
The announcement is a primary disclosure for STTK, offering a new trial milestone that may affect its valuation.
What to watch
Cash runway to 2029 reduces immediate financing risk, supporting longer‑term upside.
Background
Shattuck Labs (NASDAQ:STTK) is a clinical‑stage biotech developing DR3‑blocking antibodies. The company previously reported a Phase 1 trial for SL-325 in Crohn's disease.
Ticker impact
Shattuck Labs announced initiation of a Phase 2 trial for SL-325 in hidradenitis suppurativa and appointed a new SVP of Clinical Development.
potential modest upside as investors price in future data, but no immediate catalyst.
Phase‑2 start is a material corporate event for a clinical‑stage biotech, yet the market typically reacts only after data releases.
Market effects
Adds to the pipeline of DR3‑targeting therapeutics, may influence peer biotech valuations.
Limited to US biotech sector; no broader regional effect.
Low; relevance confined to investors tracking clinical‑stage biotech developments.
Counterpoint
Data risk remains high; without near‑term readouts the trial may not justify price moves.
Key entities
- companyShattuck Labs, Inc.
Clinical‑stage biotech developing DR3 antibodies.
- executiveShoba Ravichandran, M.D.
Appointed Senior Vice President, Clinical Development.
